Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104871 | 0.95 | S1PR1 (0.33) | S1PR1AAK1IDO1SLC13A5MAPT | |
| SCHEMBL10104900 | 0.92 | S1PR1 (0.32) | S1PR1AAK1IDO1KDM4EMEN1 | |
| SCHEMBL10104774 | 0.92 | S1PR1 (0.33) | S1PR1AAK1IDO1KDM4EMEN1 | |
| SCHEMBL10104899 | 0.91 | IDO1 (0.35) | S1PR1AAK1IDO1MAPTTP53 | |
| SCHEMBL10104771 | 0.90 | S1PR1 (0.33) | S1PR1AAK1IDO1SLC13A5MAPT | |
| SCHEMBL2128055 | 0.90 | MAPT (0.33) | IDO1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL2128049 | 0.90 | MAPT (0.33) | IDO1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL10104873 | 0.87 | S1PR1 (0.32) | S1PR1AAK1IDO1 | |
| SCHEMBL2130049 | 0.85 | PPARG (0.33) | MAPTKDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL2130043 | 0.85 | PPARG (0.33) | MAPTKDM4EMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569270-B2 | Diphenyl sulfide derivatives and medicines containing same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20120101068-A1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101068-A1 | DIPHENYL SULFIDE DERIVATIVES AND MEDICINES CONTAINING SAME AS ACTIVE INGREDIENT | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885AAK1 3218/4885IDO1 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.